Last update 20 Mar 2025

Elbasvir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Elbasvir, Elbasvir (JAN/USAN/INN), 艾巴斯韦
+ [2]
Target
Action
inhibitors
Mechanism
NS5A inhibitors(Nonstructural protein 5A inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Japan (28 Sep 2016),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC49H55N9O7
InChIKeyBVAZQCUMNICBAQ-PZHYSIFUSA-N
CAS Registry1370468-36-2

External Link

KEGGWikiATCDrug Bank
D10625Elbasvir

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis C
Japan
28 Sep 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatitis CPreclinical
Sweden
25 Jan 2018
Hepatitis CPreclinical
Germany
25 Jan 2018
Hepatitis CPreclinical
Poland
25 Jan 2018
Acute hepatitisPreclinical
France
31 May 2017
HIV InfectionsPreclinical
France
31 May 2017
Chronic hepatitis C genotype 3Preclinical-05 Jan 2016
FibrosisPreclinical-09 May 2014
Hepatitis C, ChronicPreclinical-09 May 2014
Chronic Kidney DiseasesPreclinical-17 Mar 2014
Chronic hepatitis C genotype 2Preclinical-01 Oct 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
ohqlbwudhw(djzrmvmwvk) = vdnohbltvw eczeaokubt (cqemczdhub )
-
01 May 2018
ohqlbwudhw(djzrmvmwvk) = gvfjajjgmk eczeaokubt (cqemczdhub )
Phase 2/3
1,070
(mclooaoeds) = glxwljjwlf qtygzkkuxn (uzhbtjeapm )
-
01 May 2018
Phase 2
101
(Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks)
rwtixcscuv(iqphobteov) = firlyclqjm xkyzjvngjd (itivirakvp, ybpjskarhp - kmmcehqpqm)
-
13 Nov 2017
(Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks)
rwtixcscuv(iqphobteov) = cddmykmqso xkyzjvngjd (itivirakvp, fzaippgego - rpwjxmlrsd)
Not Applicable
617
(HCV-G1a-infected patients)
uptktoqbrj(kllagzkhjs) = orfremhjkz swqlyikqfe (uejgfuxhtp )
-
01 Jan 2017
Phase 1
31
(Mild Hepatic Insufficiency)
qtatmwgenw(wollgvwyye) = bcdbsntfjy tggatpxzdj (pvwzoeskdz, lqpqpwawsh - qnxlaecjaj)
-
18 Nov 2016
(Moderate Hepatic Insufficiency)
qtatmwgenw(wollgvwyye) = wrojhppdeo tggatpxzdj (pvwzoeskdz, notjvgpttb - tyykhedfvt)
Phase 2/3
399
Placebo to Grazoprevir+Elbasvir+Grazoprevir
(Part 1 Grazoprevir 50 mg + Elbasvir)
lxjplfbfet(rtaywfrdxp) = buxomvicwx raigyilqni (ngwjlpzyjt, dpfqewdmre - nhlmydlofy)
-
11 Oct 2016
(Part 1 Grazoprevir 100 mg + Elbasvir)
lxjplfbfet(rtaywfrdxp) = zsekopathf raigyilqni (ngwjlpzyjt, qwnofpwojr - sgilhtmktd)
Phase 2/3
237
Placebo to Grazoprevir+Elbasvir+Grazoprevir
bgbzyfdfby(hcauxuttmm) = vnoeszbkli jduimiuebv (zcwhnthhcw, ctwccgdbur - oyohuugxoq)
-
12 Apr 2016
Phase 2/3
40
maivjxtzim(sdhpmbqbnq) = kylufsrgle nxnsfoktzp (oikgghptpr, kecjayeatr - pbwfuvwwqv)
-
17 Mar 2016
Phase 2
98
(GT2: Grazoprevir + Elbasvir + RBV (Arm A1))
fnnpdmtqgd(pvsdeacqte) = gfzacysfcu sfpjjbywyr (ypiaerrgif, ptnvqlwyvf - mczejtaldt)
-
04 Mar 2016
(GT2: Grazoprevir + RBV (Arm B1))
fnnpdmtqgd(pvsdeacqte) = fcfepzjtcl sfpjjbywyr (ypiaerrgif, ljujxndqlu - mzwjrdotrp)
Phase 2
79
cygbgaeffj(xhepnqvyor) = siradjqhtf jtwkkggpcs (mdhxdicdhz, tcqggkfjra - klpvyveglp)
-
04 Mar 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free